ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Neuropsychiatric symptom subtypes and dementia-associated neuropathologic change.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plasma neurofilament light chain and regional brain atrophy mediate the association of neuropsychiatric symptoms with cognition in Alzheimer's disease: evidence from two population-based studies.Psychological medicine · 2026Article
- Article
- Neuropsychiatric symptom subtypes and dementia-associated neuropathologic change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease.Frontiers in psychiatry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionNeuropsychiatric symptoms (NPS) are prevalent in clinically diagnosed Alzheimer's disease (AD), yet their etiology remains unclear. We assessed associations between NPS and neuropathologic features in dementia patients.
methodsLogistic regression analyses estimated associations between neuropathologic lesions and retroactively assigned NPS phenotypes (early and late psychosis [EPS, LPS], early and late affective symptoms [EAS, LAS]).
resultsEPS was associated with Lewy body (odds ratio [OR] = 2.4, p < 0.0001) and white matter (OR = 1.7, p < 0.0001) pathology. LPS was associated with moderate/severe neurofibrillary tangles (OR = 2.8, p < 0.0001), moderate/frequent neuritic plaques (OR = 2.3, p < 0.0001), Lewy bodies (OR = 1.9, p < 0.0001), and cerebral amyloid angiopathy (OR = 1.6, p < 0.0001). EAS was associated with white matter injury (OR = 3.4, p < 0.0001); EAS and LAS were associated with moderate/severe neurofibrillary tangles (ORs = 1.7, 1.9, p < 0.005). Risk for EPS, LPS, and EAS increased with total neuropathologic burden. DISCUSSION: NPS subtypes are differentially associated with AD/non-AD neuropathologic features, suggesting that efficiency of interventional targets may depend upon timing and type of NPS. HIGHLIGHTS: Timing/nature of neuropsychiatric symptoms (NPS) had distinct associations with brain autopsy findings in the National Alzheimer's Coordinating Center. Increased odds for psychosis symptoms was associated with both Alzheimer's disease neuropathologic change (ADNC) and Lewy body dementia (LBD). Late psychosis symptoms (PS) was most strongly associated with ADNC, early PS most strongly with LBD. Early PS and affective symptoms were both associated with white matter disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.